ADCT

1.2751.92%
RS

Ron Squarer

Chairman of the Board

Mr. Ron Squarer, BSc (Biochemistry), MBA, served as an Independent Director of Nuvalent, Inc. from December 10, 2025 to July 15, 2026. He served as Independent Chairman at Deciphera Pharmaceuticals, Inc. since August 2023 until June 11, 2024. He serves as Chairman of the Board at ADC Therapeutics SA since March 2020. He had served as an Independent Director of Deciphera Pharmaceuticals, Inc. since December 2019 until June 11, 2024. He had been the Chief Executive Officer at ArrayBioPharma Inc. since April 2012 until July 2019. Mr. Squarer has extensive commercial, development and executive leadership expertise from career in the pharmaceutical industry. Mr. Squarer has substantial experience in late-stage drug development and commercialization. Mr. Squarer served as Corporate Vice President of Global Strategy & Business Development at Hospira Australia Pty Ltd. since February 1, 2007 and also served as its Senior Vice President of Business Development. He served as the Chief Commercial Officer and Senior Vice President of Hospira Inc., since February 2010 to April 2012, where he was responsible for delivering annual revenue and leading more than 2,000 employees worldwide. Mr. Squarer served as Senior Vice President of Global Marketing & Corporate Development at Hospira Inc. since January 2009 to 2010, responsible for strategy, new product development and commercialization, acquisitions, partnerships and portfolio prioritization and served as its Corporate Vice President of Business Development & Global Strategy from February 1, 2007 to 2008. Mr. Squarer served as Senior Vice President of Global Corporate and Business Development at Mayne Pharma Limited since 2006 to 2007. Mr. Squarer has experience in the bio-pharmaceutical industry specifically in relation to licensing, strategy and brand management. From 2004 to 2006, he served as the Oncology Therapy Area Commercial Development Leader at Pfizer Inc., focused on global oncology commercial development. Prior to Pfizer, Mr. Squarer held senior management roles at SmithKline Beecham Pharmaceuticals (now GlaxoSmithKline) in the US and Europe in brand management, country management and business development. Mr. Squarer has been an Independent Director at Travere Therapeutics, Inc. (formerly known as Retrophin, Inc.) since April 12, 2017. He served as a Director of ArrayBioPharma Inc. since April 2012 until July 30, 2019. Mr. Squarer holds a B.S. in biochemistry from the University of California, Berkeley and an M.B.A. from Northwestern University’s Kellogg School of Management.

Positions